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Graphical Abstract 
 
Highlights 
 Naproxen solid lipid nanoparticles (Nap-SLN) can successfully be prepared by ultrasonication 
 Properties of these nanoparticles can be optimized by lipid concentrations 
 HLB of the surfactants played a crucial effect on properties of solid lipid nanoparticles 
 Nap-SLN increased the drug concentration in skin layer rather than systemic absorption 
 
Abstract 
The aim of the current investigation was to produce naproxen solid lipid nanoparticles (Nap-SLNs) by 
the ultrasonication method to improve its skin permeation and also to investigate the influence of 
Hydrophilic-lipophilic balance (HLB) changes on nanoparticles properties. The properties of obtained 
SLNs loaded with naproxen were characterized by photon correlation spectroscopy (PCS), 
transmission electron microscopy (TEM) and differential scanning calorimetry (DSC). FT-IR was 
also used to investigate any interaction between naproxen and the excipients used at the molecular 
level during the preparation of the SLNs. The performance of the formulations was investigated in 
terms of skin permeation and also the retention of the drug by the skin. It was found that generally, 
with increasing the lipid concentration, the average particle size and polydispersity index (PDI) of 
SLNs increased from 94.257±4.852 nm to 143.90±2.685 nm and from 0.293±0.037 to 0.525±0.038 
respectively. The results also showed that a reduction in the HLB resulted in an increase in the PDI, 
particle size, zeta potential and entrapment efficiency (EE %). DSC showed that the naproxen 
encapsulated in the SLNs was in its amorphous form. The peaks of prominent functional groups of 
naproxen were found in the FT-IR spectra of naproxen-SLN, which confirmed the entrapment of 
naproxen in the lipid matrix. FT-IR results also ruled out any chemical interaction between drug and 
the chemicals used in the preparation of SLNs. The amount of naproxen detected in the receptor 
chamber at all the sampling times for the reference formulation (naproxen solution containing all 
surfactants at pH 7.4) was higher than that of the Nap-SLN8 formulation. Nap-SLN8 showed an 
increase in the concentration of naproxen in the skin layer with less systemic absorption. This 
indicates that most of the drug in Nap-SLN8 remains in the skin which can reduce the side effect of 
systemic absorption of the drug and increases the concentration of the drug at the site of the action.  
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1. Introduction 
The development of new drugs alone is not sufficient to ensure progress in drug therapy [1]. 
To overcome problems such as poor absorption, rapid metabolism and elimination, poor 
water solubility and high fluctuation of plasma levels, development of suitable drug delivery 
systems is a good strategy [2]. Naproxen is a non-steroidal anti-inflammatory drug (NSAID) 
which is used with increasing frequency in the treatment of rheumatic diseases and related 
painful conditions [3] . Naproxen protein binding in plasma is  high and also varied [4] and 
like other NSAIDs causes gastritis and peptic ulceration after oral administration [5]. If these 
drugs are administered topically they should be able to provide high concentration of the drug 
locally if the poor permeability of the stratum corneum is overcome [6]. In order to avoid the 
irritation of the gastrointestinal tract and minimizing the systemic toxicity, application of 
polymer-based nanoparticles such as PLGA and eudragit RL100 with controlled drug release 
pattern could be useful in the treatment of inflammatory diseases [7, 8].  One of the other 
promising methods to reduce the side effect of naproxen is the topical administration route. 
Transdermal drug delivery systems provide the most important route to achieve these goals 
[9]. The transdermal delivery system enable controlled or sustained release of the active 
ingredients and also an enhanced patient compliance [10]. Topical drug delivery however, is 
still a challenge in pharmaceutics and drug delivery due to the difficulties in controlling and 
determining the exact amount of drug that reaches the different skin layers [11]. The Active 
Pharmaceutical Ingredient (API) as well as the vehicle’s physicochemical behaviour remains 
the main factors responsible for the drug differential distribution in the skin [12-14].  
 
The bioavailability of naproxen via the percutaneous absorption is poor [15, 16] thus different 
technologies such as the pro-drug approach [6, 17, 18] and use of penetration enhancers in 
appropriate vehicles [19] have been adopted to overcome the penetration issue of naproxen 
through the skin.  
 
Recently, Solid Lipid Nanoparticles (SLN) features have been considered advantageous for 
topical administration of active substances. The great potential of SLN to improve 
prednicarbate absorption through the skin was demonstrated [20] . Another recent study 
reported that triptolide topical anti-inflammatory therapy was favoured by its entrapment in 
SLN. This strategy guaranteed an improved availability of the drug at the site of action, 
reducing the contemporary needed dose and thus, dose dependent side effects like irritation 
and staining [21] . 
 
SLNs introduced in 1991 [22], have emerged as an alternative colloidal carriers due to 
advantages such as improved physical stability, good tolerability, efficient incorporation of 
lipophilic drugs in the lipid core of the SLNs and ease of scale up and manufacturing [23]. 
These nanoparticles possess a solid lipid core matrix that is solubilized by surfactants [24]. 
 
Puglia et al., showed that SLNs containing naproxen could be used as a platform for 
prolonged topical delivery to the skin and thus enhancing the anti-inflammatory effect of the 
drug [25]. They however did not investigate how the changes in HLB of the system using 
different proportions of binary mixtures of two surfactants with different HLB values during 
the preparation of the nanoparticles can change the physicochemical properties of SLNs. The 
aim therefore of the current study was to produce naproxen solid lipid nanoparticles to 
improve its skin permeation and to fully characterize them. To the best of our knowledge 
there is no study that has investigated the two faces of HLB in the optimization of SLNs as 
such this is where the novelty of the present study lies. 
2. Materials and Methods 
2.1 Materials 
Naproxen (Nap) was purchased from Alborz bulk Co. (Tehran, Iran). Tween 80 (Samchun 
Pure Chemical Co., Ltd. Korea), Span 80 (Daejung Chemicals & Metals Co., Ltd. Korea), 
glyceryl mono stearate (GMS, (Merck Co.,Germany)) were used. Distilled water was purified 
using a Milli-Q system (Millipore, Direct-Q). 
  
2.2 Preparation of NAP-SLN  
Naproxen nanoparticles were prepared using the probe ultrasonication method, which has 
been used previously for the production of lipid nanoparticles [24]. The mixture of GMS with 
naproxen was melted at below 100 °C using a heater stirrer. The heated mixture of solid lipid 
and naproxen was then mixed with 80 mL of pre-heated surfactant solution (Tween and Span 
mixture in percentages as in table 1 in 80 mL water) to form a pre-emulsion. The mixture was 
then sonicated for 10 min at 95 °C using a probe sonicator (Bandelin, Germany). Since this 
step is carried out at a temperature greater than the melting point of the lipid, at this stage 
nanoemulsion can be present due to the liquid state of the lipid. The mixture was then 
immersed in an ice bath instantly after the sonication process finished. This cooling step 
promoted the formation of the solid lipid nanoparticles. For more details of the composition 
readers are directed to Table 1. 
 
2.3 Physicochemical characterization  
SLNs were characterized in terms of mean particle size, polydispersity index (PDI) and zeta 
potential (ZP). Briefly, Zeta potential and poly dispersity index (PDI) of the nanoparticle 
formulations were determined using Zetasizer (Nano ZA, Malvern Instruments, UK). In this 
method the sample was measured at 25 °C with an angle detection of 90°. The concentration 
of the samples for analysis on the Zeta Sizer was 20-400 kilo counts per second (KCPS) and 
the intensity of diffraction was 100000 counts per second. 
 
2.4 Entrapment efficiency  
To determine the entrapment efficiency (EE %) of Nap in the SLNs, the Nap-SLNs were 
subjected to centrifugation for 90 min at 29,000 rpm (HERMLE, Z36HK, Germany), filtered 
(pore size: 0.22 µm) and the amount of Nap in supernatant (free drug) was determined by 
HPLC Agilent 1100 at 230 nm, which was equipped with the Agilent Eclipse XDB-C18 
column (5 µm, 4.6×250 mm). The mobile phase, composed of 40:20:40 acetonitrile, 
methanol and acetic acid (1% v/v) was delivered at 0.7 ml/min. The retention time of the drug 
was 11 min. Drug entrapment efficiency (EE %) was calculated using equation 1:  
 
100% 


drug
drugdrug
initial
freeinitial
W
WW
EE          (Equation 1) 
Where Winitial drug is the amount of drug added in the formulation and Wfree drug is the amount 
of drug in supernatant [26]. 
 
2.5 Transmission Electron Microscopy (TEM) 
TEM (Hitachi H-7500, Japan) was used for morphological observation and operated at 120 
kV. Briefly, SLN samples were first diluted two times with distilled water. One drop of the 
diluted sample was placed on a 200-mesh carbon-coated copper grid, stained with 2 % 
phosphotungstic acid solution and dried at room temperature. Representative images of each 
sample were reported. 
 
 
2.6 Fourier Transforms Infrared (FT-IR) analysis  
The optimized formulations were freeze-dried and converted into solid form. A Perkin Elmer 
FT-IR spectrophotometer (Perkin FTIR-One, USA) was used to identify any changes in the 
molecular levels of naproxen, GMS, Physical mixture and Nap-SLNs from 400 to 4000 
cm
−1
.The sample was grounded with KBr and compressed into a suitable-size disk (13 mm) 
for measurement [26]. 
 
2.7 Differential Scanning Calorimetry (DSC) 
Thermal behaviors of samples were studied by differential scanning calorimetry (Pyris 6, 
PerkinElmer, USA). Prior to heating, approximately 7 mg samples were equilibrated in the 
DSC pan (hermetic crimped aluminum pans) at 20 ˚C for 30 min and then heated to 250 ˚C at 
a scanning rate of 10 ˚C/min under N2 atmosphere.   
 
2.8 Powder X-ray Diffractometer (PXRD) analysis 
Bruker D8 Advance X-ray diffractometer (Germany) (40 kV, 30 mA) was used to identify 
any changes in the crystal lattice of the materials used in making SLN. PXRD studies were 
performed on the samples Nap, GMS, physical mixture of Nap: GMS and Lyophilized 
optimized SLN by exposing them to Cu Kα radiation with a wavelength of 1.5406Å and 
scanned from 4.000º to 75.000º, 2Ø at a step size of 0.040º and step time of 1s. 
 
2.9 In vitro skin permeation study 
The abdominal skin of Wistar male rats, weighing 200-250 g, were shaved. The abdominal 
skin was surgically excised. To remove the adhering subcutaneous debris and leachable 
enzymes, the dermal side of the skin was put in contact with a saline solution for 24 h before 
starting the diffusion experiment. A system employing three improved Franz diffusion cells 
was used for permeation studies. The excised rat skin was set in place with the stratum 
corneum facing the donor compartment and the dermis facing the receptor [27]. The receiver 
compartment was filled with 5.5 ml of 50:50 ethanol/water mixture. The diffusion cells were 
maintained at 37±0.5 
o
C with stirring at 300 rpm throughout the experiment. 10 ml of Nap-
SLNs formulation as sample and naproxen solution in phosphate buffer saline (pH= 7.4) with 
equal amount of components except lipid as control was selected.  
 
Samples from the receiver medium were withdrawn at predetermined time intervals (2, 4, 6, 8 
and 24 h) and an equivalent volume of the medium maintained at 37 ºC was replaced. All 
samples were filtered through 0.22 µm filters and analyzed by the HPLC method as described 
before in section 2.4. At the end of the permeation study, to calculate the amount of Nap 
deposited within the skin, the skins were removed and washed three times with phosphate 
buffer solution (PBS, pH 7.4) and the residual washing solvent was carefully wiped off from 
the skin. The skins were minced, transferred to a test tube and digested for 24 h in a 50:50 
ethanol/water mixture and then sonicated for 1 h with a bath sonicator. The supernatant was 
then filtered through a 0.22 μm membrane and quantified by HPLC at 230 nm for Nap 
content. 
 
2.10 Statistical analysis 
All the results are expressed as the mean ± standard deviation of at least three determinations 
(n=3). The treated groups were compared to the control by analysis of variance (ANOVA), 
following Tukey test. In the case of comparison of only two means, t-test was performed. The 
statistical analysis was carried out using the SPSS software. A P-value < 0.05 was considered 
as significant. 
 
3. Results and discussion 
3.1 Effect of drug/lipid ratio on nanoparticle characterization 
The composition of the SLN formulations and their properties are listed in Table 1. It was 
found that, generally, an increase in the lipid concentration, brought about an increase in the 
particle size and PDI of SLNs (P<0.001) (compare Nap-SLN1 with Nap-SLN3 in Table 1). 
Jameel et al. also indicated that an increase in lipid level showed a significant influence upon 
particle size [28]. The results are as such in agreement with previous research studies  [28, 
29]. However, in another study on SLN loaded with meloxicam, an increase in lipid 
concentration was associated with an increase in particle size, but only when the lipid 
concentration exceeded a critical value [30]. Vitorino et al showed that, higher lipid content 
in each initial dichloromethane (DCM) droplet also promotes larger particles after solvent 
evaporation [31]. The drug entrapment efficiency of Nap-SLNs (Nap-SLN1 to Nap-SLN3) 
varied from 59.46 to 66.34 % (Table 1). The lowest EE % belonged to the formulations 
containing high concentration of lipid. This could be due to the partial expulsion of the drug 
at the particle surfaces during the crystallization of the lipid phase leading to lower EE %. 
Furthermore, when the concentration of lipid in the formulation is high, this increases the 
viscosity at the interface (between lipid phase and aqueous phase). The increase in the 
viscosity can slow down the diffusion of lipid particles into the aqueous phase [32] leading to 
low EE %. 
 
3.2 Effect of HLB on nanoparticles characterization 
The results of the effect of HLB showed that a reduction in the HLB of the surfactants causes 
an increase in the PDI (wider size distribution), particle size, zeta potential (a better stability) 
and EE % (Table 1). As the main goal of the present study was to manufacture SLNs with a 
better stability, high entrapment efficiency, smaller particles and a narrow sized distribution, 
different HLB values (between 8 and 16) in the system were produced by using different 
proportion of binary mixtures of two surfactants with two different HLBs, in order to find the 
optimum values of HLB that can fulfill the above mentioned requirements such as size, PDI, 
EE % and zeta potential. Higher EE % may be as a result of the high solubility of naproxen in 
span 80 [33]. In order to decrease the HLB value of the system, the amount of Span 80 (the 
surfactant with low HLB) should increase, therefore span 80 helps to load naproxen into the 
solid lipid. It is generally expected that the smallest emulsion droplets can be obtained when 
the optimum HLB level is attained during the manufacturing process. This could explain why 
the smallest particles with the narrower distribution were obtained for Nap-SLN4. This in 
turn can increase the stability of the formulations when binary mixtures of surfactants are 
used.  The use of binary mixtures of surfactants with low and high HLB ensure a better 
stability of emulsion droplets as the surfactant with high HLB can be dispersed in aqueous 
phase and the one with low HLB can be dispersed in oily phase leading to the stability of the 
surfactant film at the interface from the reservoir created in each phase [9]. The values of zeta 
potential reduced as the HLB value of the system reduced. Beyond the optimum HLB value 
the zeta potential of the particles increased significantly.  Although Tween 80 and Span 80 
are non-ionic surfactants, the zeta potential of the droplets has gone up to −10.5 mV which 
could be due to residual electrolyte coming from the ethoxylation catalyst described by 
Abismaıl, et al.,  [34] and this effect increases with an increase in the span 80 concentration. 
 
3.3 TEM analysis 
In order to show microscopy images of nanoparticles, Nap-SLN6 was selected as one of the 
formulations with narrower distribution and its microscope image is presented in Figure 1. 
This image reveals that the particles were segregated, uniform in size and spherical in shape. 
The particle size observed by TEM imaging technique was less than dynamic light scattering 
technique using zeta-sizer probably because the nanoparticles get dehydrated while preparing 
for TEM analysis. Zetasizer tends to measure the apparent diameter of the particles, including 
the hydrodynamic layers surrounding the particles, resulting in an overestimated particle size 
[35]. 
 
3.4 FT-IR  
Figure 2 illustrates the infrared spectra of naproxen, GMS, Nap-SLN6 and physical mixture 
(with the same composition). Nap shows diagnostic bands at 3193 cm
-1 
(OH, stretching), 
2939 cm
-1
 (C-H, stretching), 1728 cm
-1
 (non-hydrogen- bonded –C=O, stretching), 1684 cm-1 
(hydrogen-bonded –C=O, stretching), 1604 cm-1 and 1504-1453 cm-1 (aromatic C=C, 
stretching), 1264 cm
-1
 (Aryl-O, asymmetric stretching), 1091 cm
-1
 (C-O, stretching) and 1029 
cm
-1 
(Aryl-O, symmetric stretching). Some of these diagnostic bands (e.g.,1605 cm
-1
 and 
1028 cm
-1
) were found in Nap-SLN6 or in the physical mixture formulation but with smaller 
intensity due to less concentration of naproxen in the formulation compared to pure naproxen.  
GMS shows bands at 3400-3200 cm
-1
 (OH, stretching), 3000-2850 cm
-1
 (C-H, stretching), 
1731 cm
-1
 (C=O, stretching) and 1300-1000 cm
-1
 (C-O, stretching). Both naproxen and GMS 
have carbonyl groups peaks which shifted and were almost overlapped. The peak shifts were 
small, two peaks were near to each other but still recognizable, which revealed entrapment of 
naproxen in lipid matrix. FT-IR results also proved no chemical interaction between drug and 
its carriers. Similar conclusion was drawn for other formulations. 
 
3.5 Differential scanning calorimetry (DSC) 
The pure naproxen, bulk GMS, the physical mixture and Nap-SLNs powder were examined 
by DSC and their DSC traces are shown in Figure 3. Naproxen showed a single sharp 
endothermic melting peak at about 154 ºC corresponding to its melting point, indicating its 
characteristic crystalline nature. Bulk GMS showed a single endothermic melting peak 
around 56-67 ºC. As observed in Figure 3, the DSC trace of Nap-SLN6 and its physical 
mixture contained the endothermic peak around the GMS melting point. The endothermic 
peak of crystalline form of drug disappeared. This suggests conversion of crystalline 
naproxen to the amorphous form which could be attributed to complete dissolution of the 
drug in the molten lipid matrix. This phenomenon was also true for all the Nap-SLN 
formulations investigated.  
 
3.6 Powder X-ray Diffractometer (PXRD) analysis 
Figure 4 shows the X-ray diffraction (PXRD) pattern of Nap. Nap manifested the distinct 
peaks at 2θ: 6.5°, 12.4°, 16.6°, 19°, 20°, 22.5°, 24° and 28.5° indicating the highly crystalline 
nature of the drug. The PXRD pattern of GMS showed a peak at about 20°, indicating the 
crystalline nature of the lipid. In case of Nap-SLN the principal peak of naproxen is absent in 
PXRD spectra (Figure 4). Furthermore, the principal peak of lipid did not shift but had a 
reduced intensity as compared to the free lipid. This may be attributed to the incorporation of 
naproxen between the parts of the lipid, leading to a change in the crystallinity of the Nap-
SLNs. 
 
3.8 In vitro percutaneous absorption study 
Rat skin was used in the percutaneous absorption study. Although it has been widely 
reported that the human skin can provide more reliable skin absorption data compared 
to rat skin [36-37], such studies most of the time is not feasible particularly during the 
initial development of a novel pharmaceutical formulation.  In addition, it is generally 
accepted that the human skin is less permeable than rat skin [38], however, as this study 
aimed to determine the performance of the formulation made with that of previous 
studies where the rat skin model was used, the authors therefore opted to use the rat 
skin model also to allow for such a comparison to be made. Figures 5 and 6 shows the 
cumulative plots of the amount of naproxen that penetrated through rat skin (transdermal 
delivery) as a function of time and the amount of naproxen that penetrated to the skin layers 
(dermal delivery) respectively. In order to evaluate the skin targeting potential of SLN, the 
permeation ability of Nap into and through the skin was evaluated using Franz diffusion cells. 
The solution containing 0.0625 % naproxen, 0.851 % Tween 80 and 1.149 % Span 80 
(similar to  SLN8 formulation) in phosphate buffer (pH=7.4) was used as the standard to 
evaluate the skin permeation and skin absorption versus the Nap-SLN8 formulation. The 
amount of Nap measured in the receptor chamber for the reference formulation was higher 
than when nanoparticle formulation (Nap-SLN8) was used (p<0.05) (Figure 5), whereas the 
amount of Nap remaining in the skin layers for nanoparticle formulation (Nap-SLN8) was 
much higher than the reference formulation (p<0.05)(Figure 6). This highlights the property 
of the Nap-SLN8 formulation to decrease systemic uptake and systemic adverse effects and 
thus improving the drug levels achieved at the site of disease. Furthermore, a prolonged anti-
inflammatory effect could be shown for drug loaded SLNs compared to drug solution [25, 
39]. Francesco et al also showed that the use of  SLN can improve the oil accumulation of the 
formulation into the skin, while in case of the control solution (conventional formulation) the 
oil permeation occurred through the skin (less oil in the skin layers) [40]. Puglia et al also 
demonstrated that the particles were able to reduce the drug penetration, but increasing, 
simultaneously, the permeation and the accumulation in the horny layer [25]. These 
researchers showed that the anti-inflammatory effect drugs can be prolonged in the case of 
drug loaded nanoparticles compared to the drug solution [25]. The results obtained in the 
present study and the in vivo data published previously demonstrated that lipid nanoparticles 
are promising in drug delivery and stimulating new and deeper investigations in the field. 
4. Conclusion 
The present study showed that solid lipid nanoparticles loaded with naproxen can be 
successfully manufactured using the probe ultrasonication technique and could be suitable 
carriers for the skin and for the local delivery of naproxen. It has been shown previously that 
SLNs increase the dermal delivery of the drug with a less delivery of the drug into deeper 
layers of the skin for systemic absorption. The results showed that SLN formulation can 
increase the concentration of the drug at the top layers of the skin compared to the drug 
solution formulation containing the same components as the SLN. The results showed 
that a reduction in HLB increased PDI, particle size, zeta potential and the entrapment 
encapsulation. This indicates that the HLB value of the surfactants used in the manufacture of 
SLNs can thus control the physiochemical properties of SLNs to achieve the desired 
properties. The present study emphasizes that the concentration of naproxen in the skin layers 
is higher when SLNs were used compared to the reference formulation (naproxen solution 
containing all surfactants). Solid state analysis also showed that naproxen was in its 
amorphous state in the nanoparticle formulations.  
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Figure 1. Various TEM micrographs of Nap-solid lipid nanoparticles (Nap-SLN6) with 
different magnifications. 
 
 
 
 
  
 
 
Figure 2. FT-IR spectra of naproxen, GMS, Nap-GMS physical mixture and Nap-SLN6. 
 
 
 
 
 
 
 
  
 
 
 
Figure 3. DSC traces of Naproxen, GMS, Nap-GMS physical mixture and Nap- SLN6. 
 
 
 
 
Figure 4. XRD of Naproxen, GMS and Nap-SLN6. 
 
 
 
 
 
 
Figure 5. Cumulative amount of naproxen permeated across rat skin (data is mean and 
standard deviation of three determinations, n=3; ANOVA test followed by Tukey’s test 
showed that the effect of time and formulation on naproxen permeation was significant 
p<0.05). Sample represents Nap-SLN8 and standard is naproxen solution containing the same 
concentration of surfactants used in SLN8 at pH 7.4. 
 
 
 
 
 
 
 
 
 
  
Figure 6. Amount of naproxen penetrating to the skin layers (Dermal delivery) (error bars are 
standard deviation, sample represents Nap-SLN8 and standard formulation is the naproxen 
solution at pH 7.4; t-test was carried out between the sample and standard. The difference 
was significant p<0.05; n=3). 
 
 
 
 
 
 
 
 
 
Table 1: Component and physicochemical properties of investigated NAP-loaded SLN (% w/w). The data are the mean and standard deviation of 
three determinations (n=3). NAP: naproxen; GMS: glyceryl monostearate; PDI: polydispersity index; zeta potential; EE: entrapment efficiency 
 
Formulation Naproxen 
(%) 
GMS 
(%) 
Span 80 
(%) 
Tween 80 
(%) 
Water  
(%) 
HLB Particle Size* 
(nm) 
PDI** Zeta 
Potential** 
(mv) 
EE%*** 
Nap-SLN1 0.061 0.305 0.651 1.302 Qs 100 11.4 94.3±4.9 0.293±0.037 -7.55±0.23 66.35±1.10 
Nap-SLN2 0.061 0.609 0.649 1.298 Qs 100 11.4 105.5±5.2 0.404±0.012 -7.15±1.09 59.46±0.50 
Nap-SLN3 0.060 1.210 0.645 1.290 Qs 100 11.4 143.9±2.7 0.525±0.038 -7.10±0.46 59.83±1.15 
Nap-SLN4 0.061 0.305 - 1.954 Qs 100 14.9 84.5±2.0 0.273±0.044 -4.96±0.16 59.95±0.74 
Nap-SLN5 0.061 0.305 0.210 1.744 Qs 100 13.8 100.0±9.7 0.270±0.107 -3.92±0.71 60.24±0.32 
Nap-SLN6 0.061 0.305 0.488 1.465 Qs 100 12.3 140.7±18.3 0.241±0.020 -5.06±0.78 61.64±0.37 
Nap-SLN7 0.061 0.305 0.814 1.115 Qs 100 10.5 162.2±24.2 0.351±0.046 -7.05±2.21 62.45±0.13 
Nap-SLN8 0.061 0.305 1.122 0.831 Qs 100 8.7 252.6±43.1 0.394±0.081 -10.57±0.57 62.91±1.79 
ANOVA test followed by Tukey’s test showed that the effect of HLB on particle size, PDI, zeta potential and EE% was significant (p<0.05). *In 
the particle size column all the particle sizes are significantly different from each other (Tukey’s test); **The effect of HLB on PDI and zeta 
potential is more dominant when the difference in the HLB value is more than 1.8 (for example there is no significant difference between Nap-
SLN8 and Nap-SLN7, but this difference was significant when Nap-SLN8 was compared to Nap-SLN6). ***Nap-SLN1 is significantly different 
from the other formulations. The difference between SLN3, SLN4, SLN5, SLN6 and SLN7 is not significant (p>0.05). The difference between 
SLN4 with SLN8 and SLN5 and SLN8 is significant (p<0.05).  
